Abstract

The Revised Trauma Score (RTS) has been proposed as an entry criterion to identify patients with mid-range survival probability for traumatic hemorrhagic shock studies. Determination of which of four RTS strata (1-3.99, 2-4.99, 1-4.99, and 2-5.99) identifies patients with predicted and actual mortality rates near 50% for use as an entry criterion in traumatic hemorrhagic shock clinical trials. Existing database analysis in which demographic and injury severity data from two prior international Diaspirin Cross-Linked Hemoglobin (DCLHb) clinical trials were used to identify an RTS range that could be an optimal entry criterion in order to find the population of trauma patients with mid-range predicted and actual mortality rates. Of 208 study patients, the mean age was 37 years, 65% sustained blunt trauma, 49% received DCLHb, and 57% came from the European Union study arm. The mean values were: ISS, 31 (SD = 18); RTS, 5.6 (SD = 1.8); and Glasgow Coma Scale (GCS), 10.4 (SD = 4.8). The mean TRISS-predicted mortality was 34% and the actual 28-day mortality was 35%. The initially proposed 1-3.99 RTS range (n = 41) had the highest predicted (79%) and actual (71%) mortality rates. The 2-5.99 RTS range (n = 79) had a 62% predicted and 53% actual mortality, and included 76% blunt trauma patients. Removal of GCS <5 patients from this RTS 2-5.99 subgroup caused a 48% further reduction in eligible patients, leaving 41 patients (20% of 208 total patients), 66% of whom sustained a blunt trauma injury. This subgroup had 54% predicted and 49% actual mortality rates. Receiver operator curve (ROC) analysis found the GCS to be as predictive of mortality as the RTS, both in the total patient population and in the RTS 2-5.99 subgroup. The use of an RTS 2-5.99 inclusion criterion range identifies a traumatic hemorrhagic shock patient subgroup with predicted and actual mortality that approach the desired 50% rate. The exclusion of GCS <5 from this RTS 2-5.99 subgroup patients yields a smaller, more uniform patient subgroup whose mortality is more likely related to hemorrhagic shock than traumatic brain injury. Future studies should examine whether the RTS or other physiologic criteria such as the GCS score are most useful as traumatic hemorrhagic shock study entry criteria.

Highlights

  • The Revised Trauma Score (RTS) has been proposed as an entry criterion to identify patients with mid-range survival probability for traumatic hemorrhagic shock studies

  • The US study involved 98 patients enrolled in the efficacy trial in 17 US trauma centers from February 1997 through January 1998; the European Union (EU) study enrolled 121 patients in four Belgian, 17 French, and 11 German trauma centers from July 1997 through May 1998.14,26 Inclusion criteria required that patients have hemorrhage and proven hypoperfusion (SBP,90 mm Hg and HR .120 beats/ min, systolic blood pressure (SBP),90 mm Hg and HR,60 beats/minute, or base deficit .15 mEq/L)

  • The patients from the two traumatic hemorrhagic shock clinical trials were utilized for this analysis because they most accurately represented the population of patients that may be studied in future resuscitation trials using hemoglobin-based solutions

Read more

Summary

Introduction

The Revised Trauma Score (RTS) has been proposed as an entry criterion to identify patients with mid-range survival probability for traumatic hemorrhagic shock studies. Hypothesis/Problem: Determination of which of four RTS strata (1-3.99, 2-4.99, 1-4.99, and 2-5.99) identifies patients with predicted and actual mortality rates near 50% for use as an entry criterion in traumatic hemorrhagic shock clinical trials. Removal of GCS ,5 patients from this RTS 2-5.99 subgroup caused a 48% further reduction in eligible patients, leaving 41 patients (20% of 208 total patients), 66% of whom sustained a blunt trauma injury This subgroup had 54% predicted and 49% actual mortality rates. Conclusion: The use of an RTS 2-5.99 inclusion criterion range identifies a traumatic hemorrhagic shock patient subgroup with predicted and actual mortality that approach the desired 50% rate. Mortality from traumatic hemorrhagic shock remains high despite optimal resuscitation efforts.[1,2,3,4,5,6] To improve trauma patient outcome, there has been a sustained effort to develop a hemoglobin-based oxygen carrier (HBOC) solution that could be used as a resuscitation fluid in the prehospital or military field setting.[7,8,9,10] The development of such a solution requires the use of clinical trials that demonstrate the effects of a potential resuscitation fluid.[11,12,13] In order to assess the efficacy of an HBOC solution in traumatic hemorrhagic shock, the study population must demonstrate improved survival with use of Received: August 12, 2011 Accepted: April 3, 2012 Revised: May 11, 2012

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call